Dem senators question Giuliani's relationship with OxyContin maker

Dem senators question Giuliani's relationship with OxyContin maker
© UPI Photo

Two Democratic senators are questioning whether Trump lawyer Rudy Giuliani’s past representation of an opioid manufacturer led the company to receive lenient treatment from the federal government.

Sens. Maggie HassanMargaret (Maggie) HassanOvernight Health Care — Sponsored by America's 340B Hospitals — Dems blast rulemaking on family planning program | Facebook may remove anti-vaccine content | Medicare proposes coverage for new cancer treatment Trade official warns senators of obstacles to quick China deal Actor Chris Evans meets with Democratic senators before State of the Union MORE (D-N.H.) and Sheldon WhitehouseSheldon WhitehouseGOP Green New Deal stunt is a great deal for Democrats Pence met with silence after mentioning Trump in Munich speech New battle lines in war over Trump’s judicial picks MORE (D-R.I.) sent separate letters to the Department of Justice (DOJ) and the Drug Enforcement Agency (DEA) this week asking whether Giuliani’s work years ago on behalf of both agencies while he was representing Purdue Pharma may have led to unduly lenient treatment for the company.

Giuliani, the former mayor of New York who joined President TrumpDonald John TrumpMcCabe says he was fired because he 'opened a case against' Trump McCabe: Trump said 'I don't care, I believe Putin' when confronted with US intel on North Korea McCabe: Trump talked to me about his election victory during 'bizarre' job interview MORE’s personal legal team in April to lead the response to special counsel Robert MuellerRobert Swan MuellerSasse: US should applaud choice of Mueller to lead Russia probe MORE's investigation into potential collusion between the Trump campaign and Russia in its election interference efforts, was hired by Purdue in 2002 and represented the company in the mid-2000s.


Purdue manufactures OxyContin, and the company has come under fire for its alleged deceptive and fraudulent marketing of the drug. The company is accused of intentionally misleading the public by hiding the drug’s potential for abuse.

Purdue is currently facing dozens of lawsuits for the role OxyContin has allegedly played in America's opioid epidemic.

In the letters, the senators cite reports that Giuliani represented Purdue in negotiations with the DOJ over the fraudulent marketing schemes.

At the same time, Giuliani’s firm was reportedly part of a $1 million consulting contract with the DOJ to provide advice on reorganizing its major drug investigations and Giuliani was also personally raising money for a DEA museum.

Ultimately, political appointees at the DOJ accepted a plea from Purdue that it “misbranded” OxyContin, and the company paid a $640 million fine in 2007.

Giuliani also participated in meetings with DEA officials and helped broker a deal where Perdue paid a $2 million fine for record-keeping violations but admitted no wrongdoing, the senators said.

“These facts suggest [DOJ and] DEA officials may have agreed to an inappropriately lenient treatment of Purdue Pharma simply because it was represented by Mr. Giuliani,” the senators wrote in the letters.

“The public health consequences of that decision may have been immense, and deserve greater scrutiny by Congress, [DOJ], and DEA,” the lawmakers added.

The Senators asked for DEA and DOJ to respond by Sept. 21.